Lee's, Shenogen to develop cancer combo therapy

Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) and Shenogen Pharma Group Ltd. (Beijing, China) plan to develop a combination therapy in China to treat late-stage cancers. The partners intend to investigate Pexa-Vec pexastimogene devacirepvec ( JX-594, TG6006), an oncolytic virus candidate from Lee's, in combination with Shenogen's icaritin ( SNG-162).

The partners expect synergistic effects from the combo based on animal studies. Financial terms of their deal were not disclosed. Neither company responded to inquiries. ...